文献速递血液净化与透析

口服枸橼酸铁水合物较静脉蔗糖氧化铁氧化应激更少

Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide.
PubMed 文献 · Kidney Int Rep · 2017-11-03

本研究在6例稳定血液透析患者中比较口服枸橼酸铁水合物(FC,480mg铁)与静脉蔗糖氧化铁(FO,40mg铁)的铁代谢及氧化炎症影响。结果显示两者均升高血清铁和转铁蛋白饱和度,但FO增加总铁结合力并产生非转铁蛋白结合铁,伴髓过氧化物酶升高和硫氧还蛋白下降,而FC无此变化。提示口服FC氧化应激更少。

要点

  • 口服FC与静脉FO均升高血清铁和转铁蛋白饱和度
  • 静脉FO产生非转铁蛋白结合铁并诱导氧化应激
  • 口服FC未引起氧化应激标志物变化

核心结论

  • 口服FC较静脉FO产生更少非转铁蛋白结合铁和氧化应激,可能对血透患者肾性贫血补铁有临床益处。

研究设计与样本

  • 在6例稳定血液透析患者中,于每周第一次透析空腹状态下依次接受三种方案:空白对照、口服FC 480mg铁、静脉FO 40mg铁,观察6小时。

主要发现

  • FC和FO均显著升高血清铁和转铁蛋白饱和度。
  • FO组总铁结合力显著增加(出现非转铁蛋白结合铁),FC组无变化,尽管FO组血清铁水平较低。
  • 与对照相比,FO组血清髓过氧化物酶(氧化标志物)增加伴硫氧还蛋白(抗氧化剂)显著下降,FC组无变化。

临床怎么用

  • 血透患者肾性贫血补铁时可考虑口服FC以减少氧化应激,但需结合患者具体情况个体化选择。

局限性

  • 样本量仅6例,观察时间6小时,结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A recent study suggested that orally dosed ferric citrate hydrate (FC) corrects renal anemia in patients on hemodialysis (HD), suggesting biological differences in effects of iron supplementation using different routes of administration. To address this issue, the present study compared oral FC with i.v. saccharated ferric oxide (FO) in stable HD patients. METHODS: Participants comprised 6 patients administered 3 consecutive protocols in the first HD session of the week in a fasting state: nothing given, as control (C); oral load of FC (480 mg iron), and 5 minutes of i.v. FO (40 mg iron). Iron dynamics in the body and biological impact on redox-inflammation status during the study (6 hours) were examined. RESULTS: Significant increases in serum iron and transferrin saturation were seen with both FC and FO. Regarding total iron-binding capacity as the sum of serum iron and unsaturated iron-binding capacity, no changes were found in FC, whereas significant increases were seen in FO (appearance of non-transferrin-binding iron [NTBI]), despite the lower serum iron levels in FO. Compared with C, increases were seen in serum myeloperoxidase (oxidative marker) with accompanying significant decreases in thioredoxin (antioxidant) in FO, whereas no changes were found in FC. CONCLUSION: Oral FC differs from i.v. FO in areas such as less NTBI generation and less induction of oxidative stress. The result indicates potential clinical benefits of oral FC in terms of iron supplementation for renal anemia in HD patients.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Nakayama M, Tani Y, Zhu WJ, et al. Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide. Kidney Int Rep. 2017. PMID: 29725640. doi:10.1016/j.ekir.2017.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。